Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma by Oshiro Yukio et al.
Inflammation-based prognostic score is a
useful predictor of postoperative outcome in
patients with extrahepatic cholangiocarcinoma
著者 Oshiro Yukio, Sasaki Ryoko, Fukunaga Kiyoshi,
Kondo Tadashi, Oda Tatsuya, Takahashi Hideto,
Ohkohchi Nobuhiro
journal or
publication title
Journal of hepato-biliary-pancreatic sciences
volume 20
number 3
page range 389-395
year 2013-03
権利 (C) Japanese Society of
Hepato-Biliary-Pancreatic Surgery and Springer
2012. The original publication is available at
www.springerlink.com. 
URL http://hdl.handle.net/2241/00122564
doi: 10.1007/s00534-012-0550-6
ORIGINAL ARTICLE 1 
Inflammation-based prognostic score is a useful predictor of postoperative outcome in 2 
patients with extrahepatic cholangiocarcinoma 3 
 4 
Yukio Oshiro, Ryoko Sasaki, Kiyoshi Fukunaga, Tadashi Kondo, Tatsuya Oda, 5 
Hideto Takahashi, Nobuhiro Ohkohchi 6 
 7 
Y. Oshiro, R. Sasaki*, K. Fukunaga, T. Kondo, T. Oda, N. Ohkohchi 8 
Department of Organ Transplantation Gastroenterological and Hepatobiliary Surgery, 9 
University of Tsukuba, Graduate School of Comprehensive Human Sciences, 1-1-1 10 
Tennodai, Tsukuba, 305-8575, Japan 11 
H. Takahashi 12 
Department of Epidemiology, University of Tsukuba, Graduate School of Comprehensive 13 
Human Sciences, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan 14 
 15 
*Corresponding address: 16 
Ryoko Sasaki, M.D., Ph.D. 17 
Department of Organ Transplantation Gastroenterological and Hepatobiliary Surgery,  18 
University of Tsukuba, Graduate School of Comprehensive Human Sciences, 19 
1-1-1 Tennodai, Tsukuba, 305-8575, Japan 20 
Tel + 81-29-853-3221 21 
Fax + 81-29-853-3222 22 
Email: rsasaki.dr@hotmail.co.jp 23 
Key words: Glasgow prognostic score, C-reactive protein, albumin, systemic inflammatory 24 
1 
 
response, extrahepatic cholangiocarcinoma 1 
Word Count: 3702. Number of Figures: 3. Number of Tables: 4. 2 
3 
2 
 
Abstract 1 
Background/purpose: Recent studies have revealed that the Glasgow prognostic score 2 
(GPS), an inflammation-based prognostic score, is useful for predicting outcome in a 3 
variety of cancers. This study sought to investigate the significance of GPS for 4 
prognostication of patients who underwent surgery with extrahepatic cholangiocarcinoma. 5 
Methods: We retrospectively analyzed a total of 62 patients who underwent resection for 6 
extrahepatic cholangiocarcinoma. In 62 patients we calculated the GPS as follows: Patients 7 
with both an elevated C-reactive protein (CRP) (>10 mg/L) and hypoalbuminemia (<35 8 
g/L) were allocated a score of 2. Patients with either one or none of these abnormalities 9 
were allocated a score of 1 or 0, respectively. Prognostic significance was analyzed by the 10 
log-rank test and a Cox proportional hazards model. 11 
Results: Overall survival rate was 25.5% at five years for all 62 patients. Venous invasion 12 
(p=0.01), pathological primary tumor (pT) category (p=0.013), lymph node metastasis (pN) 13 
category (p<0.001), TNM-stage (p<0.001), and GPS (p=0.008) were significantly 14 
associated with survival by univariate analysis. A Cox model demonstrated that increased 15 
GPS was an independent predictive factor with poor prognosis. 16 
Conclusions: The preoperative GPS is a useful predictor of postoperative outcome in 17 
patients with extrahepatic cholangiocarcinoma. 18 
19 
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Introduction 1 
Of all gastrointestinal malignancies, pancreatobiliary carcinomas continue to have poor 2 
survival rates.1-12 Multiple studies have examined potential prognostic factors in patients 3 
undergoing resection for extrahepatic cholangiocarcinoma, including the presence of lymph 4 
node metastases,2,3,5,6,8-12 the number of lymph node metastases,11,12 resection margin,1,3,5-9 5 
tumor differentiation,1,9 and depth of invasion.7,12 There is increasing evidence that the GPS, 6 
a score based on the systemic inflammatory response (SIR) that evaluates CRP and albumin 7 
serum levels, is a useful scoring system to determine the prognosis of patients with 8 
advanced cancers.13-15 The SIR encompasses the infiltration of proinflammatory 9 
lymphocytes, which produce cytokines and chemokines within the tumor 10 
microenvironment, predisposing the tumor to further progression, invasion, and 11 
metastases.16 A state of chronic inflammation is thought to play a key role in the initiation, 12 
promotion, and progression of malignant diseases.17 13 
To our knowledge, the GPS has not been investigated in patients with extrahepatic 14 
cholangiocarcinoma. This study sought to examine the relationship between an 15 
inflammation-based prognostic score, Glasgow prognostic score (GPS), and survival in 16 
patients undergoing resection for extrahepatic cholangiocarcinoma. In addition, we 17 
evaluated the relative prognostic power of the GPS in comparison to other 18 
clinicopathologic factors after surgical resection. 19 
20 
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Patients and Methods 1 
This study retrospectively analyzed 62 consecutive patients (41 men and 21 women) 2 
with extrahepatic cholangiocarcinoma who underwent surgical resection at Tsukuba 3 
University Hospital between January 2001 and December 2009. Mean patient age was 69.0 4 
years (range; 34 to 88 years). The mean value of preoperative serum total bilirubin level 5 
was 7.1 ± 6.9 mg/dl and 36 patients (58%) had preoperative biliary drainage due to 6 
obstructive jaundice (Table 1). The appropriate biliary drainage procedures were performed 7 
in the 36 patients. Twenty-four patients underwent percutaneous transhepatic biliary 8 
drainage (PTBD), 10 patients underwent endoscopic nasogastric biliary drainage (ENBD), 9 
and 2 patients underwent endoscopic retrograde biliary drainage (ERBD). 10 
The predominant sites of the primary tumor were the hilar bile duct in 17 patients (27%), 11 
proximal bile duct in 15 patients (24%), middle bile duct in 12 patients (19%), and distal 12 
bile duct in 18 patients (30%). The appropriate surgical procedures depended on the 13 
location of the primary tumor. Twenty-five patients underwent hepatectomy with 14 
extrahepatic bile duct resection (Hx), 24 patients underwent a pancreaticoduodenectomy 15 
(PD) or subtotal stomach-preserving pancreaticoduodenectomy (SSPPD), 11 patients 16 
underwent extrahepatic bile duct resection (EBDR), and 2 patients underwent a combined 17 
hepatectomy and pancreaticoduodenectomy (HPD) (Table 1). Systemic regional 18 
lymphadenectomy, which involved resection of the lymph nodes in the hepatoduodenal 19 
ligament, posterior pancreatoduodenal nodes, and along the common hepatic artery, was 20 
performed in all patients.   21 
After surgical resection, we opened the extrahepatic bile duct longitudinally. Specimens 22 
were fixed in 10% formalin for several days, and then serially sectioned at 5-mm intervals. 23 
Specimens were prepared in the standard manner for microscopic examination by 24 
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hematoxylin and eosin staining. Histopathological findings were described in accordance 1 
with the tumor-node-metastasis (TNM) staging of the American Joint Committee on Cancer 2 
(AJCC) as well as the General rules for Surgical and Pathological Studies on Cancer of the 3 
Biliary Tract of the Japanese Society of Biliary Surgery (JSBS). 18, 19 Primary tumor status, 4 
lymph node category, and histopathological tumor grade were classified according to the 5 
AJCC-TNM classification system. We examined the histopathological factors of lymphatic 6 
invasion, venous, and perineural invasion and recorded our findings in accordance with 7 
JSBS guidelines. 8 
In the patients who underwent the biliary drainage procedures, we diagnosed whether 9 
they had cholangitis or not according to systemic inflammatory response syndrome (SIRS) 10 
criteria; including fever, abnormal white blood cell count, tachypnea, and tachycardia, as 11 
well as filthy colored bile juice which is suspect of bile contamination. Blood samples were 12 
always taken from the patients within one week before surgery in order to confirm there 13 
were no other problems or abnormality in the patients prior to receiving anesthesia and 14 
surgery. We used the blood sample data at that time; i.e., serum CRP and albumin for the 15 
GPS system. In the present study, we used the blood sample data for the GPS system in 16 
accordance with the above mentioned way by which we had diagnosed no cholangitis. We 17 
routinely investigated bacterial culture of the drained sample bile juice in the patients who 18 
underwent the biliary drainage procedures. In the culture of the bile juice in 36 patients who 19 
underwent the biliary drainage procedures, we confirmed negative pathogenic bacteria in 20 
15 patients and normal bacterial flora in 15 patients. Data was not found in the other 6 21 
patients. It is said that after the biliary drainage procedures, secondary exogenous 22 
contamination of bile juice occurs in most patients 20, so we always use antibiotics for 2-3 23 
days just after the drainage procedures. In fact, only 4 of 36 patients had fever after the 24 
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biliary drainage procedures and their fever went down soon, and the serum bilirubin level 1 
decreased gradually in all patients. After we confirmed that the patients had no cholangitis, 2 
they underwent surgical resection 31.1 (mean, range; 6-88) days after the biliary drainage 3 
procedures. The coefficient of variation for these methods, over the range of measurement, 4 
was less than 5%, as established by routine quality control procedures. 5 
Briefly, patients with both an elevated CRP level (>10 mg/L) and hypoalbuminemia 6 
(<35 g/L) were allocated a score of 2, while patients with only one of these biochemical 7 
abnormalities were allocated a score of 1. Patients with neither of these abnormalities were 8 
allocated a score of 0, as described previously. 13-15 9 
Patients were followed regularly in outpatient clinics every 1-6 months. Follow-up 10 
information for all 62 patients was obtained from records of routine clinic appointments and 11 
telephone calls to the patients and their referring physicians. Sites of disease recurrence 12 
were determined from imaging studies including computed tomography (CT) and magnetic 13 
resonance imaging (MRI). 14 
Survival curves were calculated using the Kaplan-Meier method.21 Differences between 15 
curves were evaluated using the log-rank test. P values < 0.05 were considered statistically 16 
significant. We used a multivariate Cox proportional hazard model to determine if factors 17 
independently affected postoperative survival.22 Correlations between GPS classification 18 
and age, predominant location, histological grade, venous invasion, pathological primary 19 
tumor (pT) category, lymph node metastasis, and TNM-stage were analyzed by the χ2 test or 20 
Fisher exact test as appropriate. Statistical analyses were performed using a statistical 21 
analysis software package (StatView version 5.0 Abacus Concepts, Inc., Berkeley, CA).  22 
23 
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Results 1 
A GPS of 0, 1, and 2 were assigned to 32, 20, and 10 patients, respectively. There were 2 
no significant differences in tumor characteristics of extrahepatic cholangiocarcinoma such 3 
as age, predominant location, histologic grade, venous invasion, pathological primary 4 
tumor (pT) category, lymph node metastasis, TNM-stage, carbohydrate antigen 19-9 5 
(CA19-9), and carcinoembryonic antigen (CEA) across the different GPS groups (Table 2). 6 
At last follow-up, 36 patients had died of tumor recurrence, while five patients had died 7 
of other causes without evidence of tumor recurrence. Two patients were alive with 8 
metastases and the other remaining 19 patients were alive without evidence of disease. One 9 
patient died within 30 days of surgical resection, and two patients died in the hospital, 10 
yielding a surgical mortality rate of 4.8%. Overall survival rates were 37.3% at three years 11 
and 25.5% at five years for all 62 patients. Venous invasion, pathological primary tumor 12 
(pT) category, lymph node metastasis (pN) category, TNM-stage, and GPS were found to 13 
be significant prognostic factors by univariate analysis (Table 3). In contrast, age, gender, 14 
predominant location, operative time, intraoperative bleeding, histological grade, lymphatic 15 
invasion, perineural invasion, surgical margin, CA19-9, and CEA were not found to be 16 
significant predictors of survival. 17 
Kaplan-Meier analysis demonstrated significant differences in survival among the GPS 18 
groups of 2 (mean survival, 12.7 months; 95%CI, 7.8-17.6 months), 1 (mean survival, 37.2 19 
months; 95%CI, 20.0-54.4 months), and 0 (mean survival, 34.1 months; 95%CI, 24.9-43.3 20 
months) (p=0.008) (Figure 1). Although there was significant difference between the GPS 21 
of 1 and the GPS of 2 (p=0.031), no significant difference was seen between the GPS of 0 22 
and the GPS of 1 (p=0.866). Considering the results of Figure 1, we aggregated the 23 
categories “GPS of 0” and “GPS of 1” into one category (“GPS of 0-1”) (Figure 2). 24 
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Kaplan-Meier analysis also demonstrated a significant difference between the GPS of 2 1 
(mean survival, 12.7 months; 95%CI, 7.8-17.6 months) and the GPS of 0-1 (mean survival, 2 
34.9months; 95%CI, 26.5-43.3 months) (p=0.002) (Figure 2). Thirty-six patients without 3 
lymph node metastases had a five-year survival of 44.2% in comparison to a five-year 4 
survival of 0% for 26 patients with lymph node metastases (P<0.001) (Figure 3). A 5 
multivariate analysis with a Cox proportional hazards model, utilizing venous invasion, 6 
pathological primary tumor (pT) category, lymph node metastasis (pN) category, and GPS, 7 
revealed that a GPS of 2 was an independent predictive factor of survival (HR=2.787, 8 
p=0.022) (Table 4). TNM-stage, pT, and pN factors are considered to have a strong 9 
correlation because pT and pN are components of TNM-stage. In fact, in our multivariate 10 
analysis, analysis including these three factors was not able to show estimators because of 11 
multicollinearity (data not shown). Therefore, we excluded TNM-stage from the 12 
multivariate analysis and adopted pT and pN, which are medically essential and impressive, 13 
to obtain medically meaningful results. 14 
15 
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Discussion 1 
McMillan and coworkers13-15, 23-26 demonstrated that GPS is a useful predictor of 2 
postoperative death for multiple cancers including non small-cell lung13, breast14, 3 
gastro-esophageal15, 23, pancreatic24, renal25, and colorectal26 cancers. The cases in these 4 
studies, however, were typically inoperable or metastatic. Recently, several reports have 5 
investigated GPS in patients with operable primary colorectal cancers. 16, 27-30 As yet, no 6 
reports have addressed the association between GPS and survival in extrahepatic 7 
cholangiocarcinoma. To our knowledge, this is the first report evaluating the use of GPS in 8 
patients undergoing resection for extrahepatic cholangiocarcinoma. 9 
In this study, a Cox proportional hazards model revealed that a GPS of 2 was an 10 
independent predictive factor of survival (Table 4). This data suggests that GPS is a 11 
prognostic factor of outcome; higher GPS portends poor tumor biology and worse survival. 12 
On the other hand, a Cox proportional hazards model revealed that lymph node metastasis 13 
had a marginal significance for survival (HR=2.066, p=0.071) (Table 4). Numerous studies 14 
have demonstrated that lymph node metastasis is the most accurate prognostic factor used 15 
for pancreatobiliary carcinoma; patients with lymph node metastases have a significantly 16 
worse survival than patients with node-negative disease. Jang et al. and Sasaki et al. 17 
reported that lymph node metastasis is a significant factor affecting patient outcome after 18 
surgery 3, 11. 19 
A wide range of systemic inflammatory responses results from infection, tissue injury, 20 
immunological disorders, and cancer. C-reactive protein (CRP) is an acute-phase protein 21 
produced by liver. The liver is central to the elaboration of the systemic inflammatory 22 
response. Cytokines such as interleukin-8 (IL-8), interleukin-6 (IL-6), and tumor necrosis 23 
factor α (TNF-α) stimulate hepatocytes to synthesize and release into the systemic 24 
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circulation a variety of acute-phase proteins, such as CRP, which initiate and sustain the 1 
systemic inflammatory response. 16, 31 McMillan et al. demonstrated that CRP 2 
concentrations were independently associated with overall survival in patients who 3 
underwent potentially curative resection for colorectal cancer.32 4 
In the past, hypoalbuminemia in cancer patients was thought to result from nutritional 5 
depletion secondary to the tumor. However, it has been postulated that reduction in albumin 6 
concentrations is secondary to the presence of the systemic inflammatory response.29 The 7 
acute phase protein response (APPR) is characterized by lower serum concentrations of 8 
several serum proteins, such as albumin and transferrin, which results from both decreased 9 
synthesis and altered distribution. Serum concentration of CRP and immunoglobulins 10 
increase due to increased synthesis.33,34 In patients with cancer, there is evidence that the 11 
stereotypical APPR, with an increase in CRP and decreased albumin, occurs across a wide 12 
range of different tumor types.31 Therefore, albumin levels may not only reflect underlying 13 
nutritional status, but also the presence of comorbidities.29 14 
The relationship between the systemic inflammatory response (GPS) and decreased 15 
survival in patients with extrahepatic cholangiocarcinoma is not clear and is likely to be 16 
complex. Ishizuka et al. 16 commented that cancer promotes the release of proinflammatory 17 
cytokines, leading in extreme cases to cachexia and malnutrition. Crozier et al. 29 suggested 18 
that an elevated GPS may reflect compromised cell-mediated immunity as an elevated CRP 19 
and hypoalbuminemia are associated with lymphcytopenia and an impaired T-lymphocytic 20 
response within tumors. Elevated CRP concentrations and hypoalbuminemia have also 21 
been shown to be associated with an up-regulation of the components of an innate immune 22 
system, including complement and macrophage activity. These results suggest that immune 23 
function is compromised prior to surgery, resulting in faster disease progression and 24 
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decreased long-term survival. There has been no clear basis of the relationship between a 1 
high GPS prior to surgery and poor survival in various cancers. However, based on the 2 
previous reports16, 29, we could speculate that there might be a kind of extrahepatic 3 
cholangiocarcinoma that produces or promotes cytokines such as IL-6 and TNF-α. 4 
Therefore, SIR induced by the cytokine causes the impaired immunity in patients, resulting 5 
in fast progression of the carcinoma and decreased survival. Furthermore, because there 6 
was a marginal significant difference in lymph node metastasis across the different GPS 7 
groups (P=0.059), a high GPS might have the characteristic of having a high tendency for 8 
lymphatic spread of the extrahepatic cholangiocarcinoma. 9 
Many previously reported prognostic factors have been evaluated only after surgery, 10 
because these were pathological factors. In contrast, GPS can easily be calculated from the 11 
serum CRP and albumin levels prior to surgery. Due to lower costs and improved 12 
convenience, preoperative GPS is a useful system to assess postoperative survival in 13 
patients with extrahepatic cholangiocarcinoma. 14 
Several limitations of this study, however, need to be addressed. This study had a 15 
retrospective design and was limited by a small number of patients. In addition, there is a 16 
possibility that the heterogeneity of the primary tumor location or the surgical procedures 17 
affected the results of this study. These results will need to be confirmed by a 18 
multi-institutional cohort of patients. 19 
GPS should be routinely used for patients with extrahepatic cholangiocarcinoma, as it 20 
can help stratify those patients who need additional treatment. Use of this classification 21 
system in the analysis of future clinical trials investigating extrahepatic cholangiocarcinoma 22 
will also help determine appropriate treatments according to disease severity. 23 
24 
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Conclusions 1 
In conclusion, preoperative GPS is a promising predictor of postoperative outcomes in 2 
patients with extrahepatic cholangiocarcinoma. 3 
 4 
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FIGURE LEGENDS 1 
Fig. 1 2 
Survival curves stratified by Glasgow prognostic score (GPS) 0, 1, and 2. 3 
There was a statistically significant difference among the three groups (five-year survival 4 
rates: GPS of 0, 26.8%; GPS of 1, 42.6%; GPS of 2, 0%) (p=0.008). While there was a 5 
significant difference between the GPS of 1 and the GPS of 2 (p=0.031), there was no 6 
significant difference between the GPS of 0 and the GPS of 1 (p=0.866). 7 
 8 
Fig. 2 9 
Survival curves stratified by Glasgow prognostic score (GPS) 0-1 and 2. 10 
There was a statistically significant difference between the GPS of 0-1 and the GPS of 2 11 
(p=0.002). 12 
 13 
Fig. 3 14 
Survival curves stratified by lymph node status. 15 
There was a statistically significant difference in survival between patients with positive 16 
lymph nodes and those with negative nodes (p<0.001). 17 



 Table 1.  Clinical and morphological features of patients  
Variable                                            Number of patients (%)  
Age (year) 
 (mean, range)                                      69.0 (34-88) 
Gender 
Male (n, %)                    41 (66) 
Female (n, %)                                       21 (34) 
Preoperative serum total bilirubin level (mg/dL) 
 (mean, range)                        7.1 (0.4-22) 
Preoperative biliary drainage (yes/no)                     36/26 
 PTBD                                             24(39) 
 ENBD                                            10(16) 
 ERBD                                             2(3)  
Site (n, %) 
Hilar                                           17 (27) 
 proximal                                       15 (24) 
 middle                     12 (19) 
 distal                                          18 (30) 
Surgery (n, %) 
 Hx                                             25 (40)                                                                                            
 PD, SSPPD                                     24 (39) 
 EBDR                                          11 (18) 
HPD                                             2 (3) 
TNM stage (n, %) 
 0                                               5 (8) 
 IA                                             9 (15) 
 IB                                            7 (11) 
 IIA                                             13 (21) 
 IIB                                             15 (24) 
 III                                              11 (18) 
 IV                                               2 (3) 
GPS (n, %) 
 0                                             32 (50)                                                                                                      
 1                                             20 (34) 
 2                                          10 (16) 
 
PTBD, Percutaneous transhepatic biliary drainage; ENBD, endoscopic nasogastric biliary drainage; 
ERBD, endoscopic retrograde biliary drainage; Hx, Hepatectomy combined with extrahepatic bile duct 
resection; PD, Pancreaticoduodenectomy SSPPD, Subtotal stomach-preserving 
pancreaticoduodenectomy; EBDR, Extrahepatic bile duct resection; HPD, Hepatectomy combined with 
pancreaticoduodenectomy; GPS, Glasgow prognostic score  
 
 
 
 
 
 
 Table 2.  Relationships between tumor characteristics of extrahepatic cholangiocarcinoma  
and GPS 
Variables               GPS 0            GPS 1            GPS 2           P-value 
Age (year)                                                                0.874 
 <70                   17                10 6 
  ≥70                  15                10  4 
Predominant location                                                 0.291 
  Hilar/proximal         17               8               7 
  Middle/distal          15               12 3 
Histological grade                                                           0.538 
  Well/moderately       27              15 7 
  Poor                 5               5                3 
Venous permeation                                                          0.668 
  Negative             21  12 5 
  Positive              11                 8                5 
T stage                                                                   0.781 
  Tis                   4                 1 0 
  T1                   6 2 2 
  T2                  8 3 2 
  T3                  10  10 4 
  T4                   4  4 2 
Lymph node metastasis                                                      0.059 
  Negative             18   15  3 
  Positive              14   5  7 
TNM stage                                                                0.14 
  0                    4 1 0 
  IA                   5               2 2 
  IB                   5 2 0 
  IIA                  4 8 1 
  IIB                  9 2 4 
  III                   5                4 2 
  IV                   0 1 1 
CA19-9 (U/ml)    0.419 
Normal                  9                6                5 
High   23 14 5 
CEA (ng/ml)      0.405 
Normal 22 15                9 
High   10 5 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.  Prognostic factors by a univariate analysis 
Factor                    Number of Patients      3-year rate (%)       5-year rate (%)         P-value 
All                  62                37.3                 25.5 
Age (year)                                                                 0.211 
  <70                  31                43.4                29.7 
  ≥70                  31                32.4             21.6 
Gender                                                                    0.408 
 Male                41               39.2              27.5 
 Female               21              33.6             22.4 
Predominant location                                                     0.053 
  Hilar/proximal       32               23.9             19.1 
  Middle/distal        30               51.4             32.1 
Operation Time (minutes)                                                     0.584 
  <600                32               37.5             25.0 
  ≥600                30               29.1              29.1 
Intraoperative bleeding                                                        0.084 
  <1300               37                47.0            29.9 
  ≥1300               25               17.0             17.0 
Histological grade                                                            0.838 
  Well/moderately 49  37.5             21.9 
  Poor                       13               40.2             40.2 
Tumor invasion 
  Lymphatic invasion                                                         0.197 
   Negative            21                54.4             43.5 
   Positive             41                30.2             18.9 
 Venous invasion                                                           0.01  
   Negative            38                48.9             36.2 
   Positive             24                16.6         0 
 Perineural invasion                                                          0.29 
  Negative                     10                56.3             28.1 
 Positive                      52               33.9            24.3 
 T stage                                                                     0.013 
 Tis                            5                80.0 60.0 
  T1                  10                40.0            40.0 
  T2                  13                48.5             32.3 
  T3                  24                35.2            21.1 
  T4 10                0                   0 
Lymph node metastasis                                                                     <0.001 
  Negative             36                54.0            44.2 
  Positive              26                16.9  0 
TNM stage                                                                 <0.001 
  0                    5                80.0            80.0 
  IA                   9                38.1            38.1 
  IB                   7               47.6             47.6 
  IIA                  13              67.9            40.7 
  IIB                  15               22.2            0 
  III                   11                 0              0 
  IV                            2                0               0 
Surgical margin                                                             0.081 
  Negative             36               43.1            31.5 
  Positive              26               29.9            17.9 
CA19-9                                                             0.595 
 Normal                      20               49.0            32.6 
 High                       42               33.9            23.3 
CEA                                                             0.461 
 Normal                      46               32.9            20.6 
 High                       16               46.8            37.4 
GPS                                                                      0.008 
  0                   32               44.6            26.8                                         
  1                   20               42.6            42.6 
  2                   10                 0              0 
  
 
 Table 4.  Multivariate analysis for survival 
Parameter                        HR              95% CI              P-Value 
Venous invasion : positive   1.237           0.561 – 2.727          0.598 
T stage : T3,4                    1.817           0.884 – 3.736       0.104 
Lymph node metastasis : positive     2.066           0.938 – 4.549             0.071 
GPS : 2                         2.787           1.153 – 6.735          0.022 
 
 GPS, Glasgow prognostic score; HR, hazard ratio; CI, confidence interval 
